Exemestane is a steroidal aromatase inhibitor that blocks the conversion of testosterone into estradiol. It is sold as Aromasin and as generic tablets.
Also known as: Aromasin.
Aromasin and generic exemestane come as 25 mg tablets.
The FDA label approves exemestane only for postmenopausal women with breast cancer: adjuvant treatment of estrogen receptor-positive early breast cancer after 2 to 3 years of tamoxifen (to complete 5 years in total), and advanced breast cancer that progressed after tamoxifen. The labeled dose is one 25 mg tablet once daily after a meal (50 mg with a strong CYP3A4 inducer such as rifampicin). In the label's food study, a high-fat breakfast raised exposure by about 59%. There is no approved use in men.
On TRT, exemestane is used off-label to lower estradiol, as an alternative to anastrozole. The American Urological Association 2018 guideline says clinicians may use aromatase inhibitors in men with testosterone deficiency who want to maintain fertility (a conditional recommendation) and notes that only hCG is FDA approved for use in males. Whether to take it, and how much, is a decision for you and your prescriber. See Estradiol (E2) on TRT for testing and context, and hCG vs enclomiphene for fertility-preserving options.
The FDA Aromasin label gives a mean terminal half-life of about 24 hours. Mean time to peak was 1.2 hours in women with breast cancer and 2.9 hours in healthy women; Dose Track uses 2 hours.
Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.